Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2007-06-08
2009-11-17
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S179100, C530S391500
Reexamination Certificate
active
07618613
ABSTRACT:
Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
REFERENCES:
patent: 3994966 (1976-11-01), Sundberg et al.
patent: 4043998 (1977-08-01), Meares et al.
patent: 4315851 (1982-02-01), Yoshikumi et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4401592 (1983-08-01), Yoshikumi et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4460559 (1984-07-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4622420 (1986-11-01), Meares et al.
patent: 4634586 (1987-01-01), Goodwin et al.
patent: 4636380 (1987-01-01), Wong
patent: 4707352 (1987-11-01), Stavrianopoulos
patent: 4722892 (1988-02-01), Meares et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4767609 (1988-08-01), Stavrianpoulos
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4824986 (1989-04-01), Gansow
patent: 4831175 (1989-05-01), Gansow et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4861579 (1989-08-01), Meyer, Jr. et al.
patent: 4921690 (1990-05-01), Beatty et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5009069 (1991-04-01), Molini
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5059518 (1991-10-01), Kortright et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162115 (1992-11-01), Pietronigro
patent: 5208008 (1993-05-01), Ranadive et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5219556 (1993-06-01), Wolfangel
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5286850 (1994-02-01), Gansoh et al.
patent: 5363846 (1994-11-01), Rubin et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5403573 (1995-04-01), Day et al.
patent: 5428154 (1995-06-01), Gansow et al.
patent: 5434287 (1995-07-01), Gansow et al.
patent: 5460785 (1995-10-01), Rhodes et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5545403 (1996-08-01), Page et al.
patent: 5545405 (1996-08-01), Page et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5620675 (1997-04-01), McBride et al.
patent: 5641637 (1997-06-01), Hudak et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5728369 (1998-03-01), Griffiths et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5766571 (1998-06-01), Ceriani et al.
patent: 5766751 (1998-06-01), Kotani et al.
patent: 5820845 (1998-10-01), Dean et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 5942210 (1999-08-01), Ultee et al.
patent: 5976492 (1999-11-01), Griffiths et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6994840 (2006-02-01), Chinn
patent: 0274394 (1988-07-01), None
patent: 0315188 (1989-05-01), None
patent: 0529645 (1993-03-01), None
patent: 8804936 (1988-07-01), None
patent: 9207466 (1992-05-01), None
patent: 9411026 (1994-05-01), None
patent: 9614879 (1996-05-01), None
Gary L. Griffiths, Antibody Radiolabeling With Isotopes of Rhenium, Cancer Therapy With Radiolabelled Antibodies, 1995, Chapter 7, pp. 77-86. cited by other.
Adams RA, “Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma,” Cancer Research, 1967, 27(1):2479-2482. cited by other.
Adams RA, et al., “Direct implantation and transplantation of human acute lymphoblastic leukemia in hamsters, SB-2,” 1968, Cancer Research, 1968, 28:1121-1125. cited by other.
Chakrabarti MC et al., “Prevention of radiolysis of monoclonal antibody during labeling,” J. Nucl. Med., 1996, 37 (8):1384-88. cited by other.
DeNardo et al., “Yttrium-90/Indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer,” J. Nucl. Med., 1995, 36:97P. cited by other.
Kozak RW, et al., “Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity,” Cancer Res., 1989, 49(10):2639-44. cited by other.
Leland JK, et al., “Electrogenerated chemiluminescence: An oxidative-reduction type ECL reaction sequence using Tripropyl Amine,” Electrochem. Soc., 1990, 137, 3127. cited by other.
Lewis et al., “A facile, water-soluble method for modification of proteins with DOTA,” Bioconj Chem., 1994, 5:565-76. cited by other.
Liu AY, et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity,” J. Immunol., 1987, 139/10:3521-26. cited by other.
Mather SJ, et al., “Labeling monoclonal antibodies with yttrium-90,” Eur. J. Nucl. Med., 1989, 15;307-312. cited by other.
Muller RJ, “Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay,” J Immunol Methods, 1980, 34(4):345-52. cited by other.
Parker BA, et al., “Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody,” Cancer Research, 1992, 50:1022s-28s. cited by other.
Pietersz GA, et al., “The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer,” Immunol. Cell Biol., 1987, 65:111-125. cited by other.
Pizzarello, Direct and indirect action. In Pizzarello and Witcofski, eds. Basic Radiation Biology, 2.sup.nd ed. Philadelphia: Lea & Febger, 1975, pp. 20-29. cited by other.
Robinson, RD et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities,” Hum. Antibod. Hybridomas, 1991, 2:84-93. cited by other.
Salako et al., “Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations,” J. Nucl. Med., 1998, 39:667-70. cited by other.
Thomas et al., Gamma-interferon administration after 90Y radiolabeled antibody therapy: survival and hematopoietic toxicity studies, Int. J. radiat. Oncol. Biol. Phys., 1995, 31:529-534. cited by other.
Brechbiel MW, et al., “Synthesis of 1-(p-Isothiocyanatobenzyl) derivatives of DPTA and EDTA. Antibody labeling and tumor-imaging studies,” Inorganic Chemistry, 1986, 25(16):2772-81. cited by other.
Chinol et al, “Generator-Produced Yttrium-90 for Radioimmunotherapy,” J. Nuclear Medicine, 1987, 28(9):1465-1470. cited by other.
Hnatowich et al., “The Preparation of DTPA-Coupled Antibodies Radiolabeled with Metallic Radionuclides: an Improved Method,” J. Immunological Methods, 1983, 65:147-157. cited by other.
Cytogen OncoScint Product Information, 1998, Internet document. cited by other.
Richardson et al., Optimization and batch production of DTPA-labeled antibody kits for routine use in .sup.111in immunoscintography, Nuclear Medicine Communications, 1987, 8:346-356. cited by other.
Goodwin et al., “Chelate Conjugates of Monoclonal Antibodies for Imaging Lymphoid Structures in the Mouse,” 1985, 26(5):493-498. cited by other.
International Search Report for PCT/US00/05061, mailed Dec. 12, 2000. cited by other.
International Preliminary Examination Report for PCT/US00/05061, mailed May 4, 2001. cited by other.
Kukis et al, “Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates”, J. Nucl. Med. 1998, 39:2105-2110. cited by other.
Griffiths et al, “Rapid, facile and quantitative radiolabeling of DOTA-hMAb conjugates with Y-90 cancer radioimmunotherapy”, Ab
Lerner David Littenberg Krumholz & Mentlik LLP
Rit Oncology, LLC
Saunders David A
LandOfFree
Method for radiolabeling antibodies with yttrium-90 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for radiolabeling antibodies with yttrium-90, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for radiolabeling antibodies with yttrium-90 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079366